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In his 1973 article, Adverse Publicity by Administrative Agencies,
Professor Ernest Gellhorn surveys the methods and mechanisms employed
by various administrative agencies in the United States and offers
suggestions for reform.' A significant principle in his work is that agency
publicity is important because it serves the dual functions to "inform or
warn" and to sanction. 2 The U.S. Food and Drug Administration ("FDA")
is one significant utilizer of publicity authority. The FDA's grant of
publicity authority is contained in 21 U.S.C. § 375(b), which states: 3
Information regarding certain goods. The Secretary may also cause to be
disseminated information regarding food, drugs, devices, tobacco
products, or cosmetics in situations involving, in the opinion of the
Secretary, imminent danger to health or gross deception of the consumer.
Nothing in this section shall be construed to prohibit the Secretary from
collecting, reporting, and illustrating the results of the investigations of
the Department. 4

Subsequent scholarship has built on Gellhorn's seminal work, focusing
on aspects of agency publicity and practices, the legal challenges to agency
publicity, the benefits and burdens of publicity, the motivations behind it,
t Author for correspondence: Jordan Paradise, J.D., Georgia Reithal Professor of Law; Co-Director,
Beazley Institute for Health Law & Policy, Loyola University Chicago School of Law, jparadise@
luc.edu.
1. Ernest Gellhom, Adverse Publicity by Administrative Agencies, 86 HARv. L. REV. 1380
(1973).
2. Id. at 1382-1418.
3. This is also enacted within the Food, Drug & Cosmetic Act, § 705(b).
4. 21 U.S.C. § 375(b). In furtherance of this statutory provision, the Department of Health,
Education and Welfare (now the Department of Health and Human Services) issued Recommendation

73-1, which the United States Food and Drug Administration ("FDA") adheres to in supporting its use
of publicity. Adverse Agency Publicity (Recommendation 73-1), 1 C.F.R. § 305.73-1 (1974). The FDA
also proposed a rule in 1977 regarding publicity policy, but never finalized it. The FDA has historically
faced litigation for use of this publicity authority, although courts have given the agency tremendous
discretion in this realm.
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the resulting public response and reputational damage, and the evolving
scope of activity in this realm. Nearly 50 years after Gellhorn's article,
Professor Nathan Cortez revisited Gellhorn's survey methodology and
results in a 2011 law review articles and a 2015 report to the Administrative
Conference of the United States, 6 urging that agencies have moved into an
era of "modern publicity" given the range of social media, internet, and
other outlets. Within the report, Cortez writes that FDA officials have
shifted their views on the use of publicity over time. Cortez notes:
Wayne Pines, former FDA Chief of Press Relations and Associate
Commissioner for Public Affairs, explains that FDA senior leadership
has long believed that Congress authorized FDA "to use publicity as an
enforcement tool." 7 Current FDA officials stress that FDA no longer
views publicity as an enforcement tool. 8

Global public health emergencies such as the current COVID-19
pandemic provide urgent context to the scope of the FDA's legal authority,
including enforcement actions and widespread public health warnings
issued through adverse publicity power to counter fraudulent and dangerous
product promotion. As has been explored in the legal scholarship, the FDA
operates differently than it did in 1973, when Gellhorn published his
findings, and now tailors its behavior to the urgency of a given situation. 9
In order to further study how the FDA is pursuing its public health mission
in the COVID era, this Article both qualitatively and quantitatively explores
recent FDA activity, through the mechanisms of publicity and warning
letters, against allegedly violative medical products promoted or advertised
for use as a treatment or prevention for COVID-19. The methodology
involves scholarly literature review, online searches of the FDA's publicly
available materials, analysis of the findings, and discussion of the
implications for public health and policy.
Part I of the Article identifies the legal and policy basis of the FDA's
authority to take actions utilizing adverse publicity and reviews the
prominent scholarly literature discussing its scope. Part II explains the
relationship between adverse publicity and enforcement from a historical
perspective, noting the evolution of FDA activities in these realms and the
use of warning letters to convey information to industry and the general

5. Nathan Cortez, Adverse Publicity by Administrative Agencies in the Internet Era, 2011 BYU

L. REv. 1371.
6. NATHAN CORTEZ, ADMIN. CONF. OF THE U.S., AGENCY PUBLICITY IN THE INTERNET ERA

(2015).
7. Id. at 31 (citing Interview with Wayne Pines, President, Regul. Servs. & Health Care, APCO
Worldwide (Jul. 7, 2015) (former FDA Chief of Press Rels. (1975-78) and Assoc. Comm'r for Pub.
Affs. (1978-82))).
8. Id.
9. See, e.g., Cortez, supra note 5; CORTEZ, supra note 6; Cortez, infra note 74.
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public. Part III utilizes a quantitative and qualitative approach to explore
the FDA's use of warning letters and publicity in the enforcement of laws
and regulations during the COVID-19 pandemic, assessing the breadth of
actions undertaken by the agency in the period of January 2020 through
June 2020. Part IV offers concluding reflections on the implications of this
activity in the context of COVID-19 as it relates to evolving notions of
enforcement and adverse publicity.
I. ADVERSE PUBLICITY

A. Authorizing and Defining Adverse Publicity
The statutory provision authorizing publicity is short, neither
providing explicit bounds for the term "publicity," nor even using the term.
The statute merely states that where, in the opinion of the Secretary, there
is a situation involving "imminent danger to health or gross deception of the
consumer," the Secretary may "cause to be disseminated information"
regarding that situation. 10 The legislative history provides little help in
deciphering the scope of this language that has come to be known as the
adverse publicity power. A previous draft of the Senate bill that eventually
became law granted the Secretary the power to report virtually all
proceedings, including initial findings, and to publicize "such information
regarding any food, drug, or cosmetic as he deems necessary in the interests
of public health and for the protection of the consumer against fraud.""
Conversely, a third draft included a clause that forbade the release of
information specifically naming brands, except in cases of imminent danger
or gross consumer deception.12
The Administrative Conference of the United States ("ACUS") has
issued Recommendation 73-1, which further discusses and guides the use
of adverse publicity by federal administrative agencies. 13 Adopted in 1973,
the recommendation draws from Gellhorn's findings and is codified in the
Code of Federal Regulations.1 4 The document, often cited as Recommendation 73-1, refers to "adverse agency publicity" as "statements made
by an agency or its personnel which invite public attention to an agency's
action or policy and which may adversely affect persons identified
10. 21 U.S.C. § 375 (2018). This authority to the Secretary of Health and Human Services is
delegated to the Commissioner of the FDA.
11. S. 1944, 73d Cong. (1933).
12. S. 2800, 73d Cong. (1934). Notably, the accompanying record confirms that the modification
of this clause was to avoid pre-judgment censure affecting a particular company or segment of the
economy. SEN. REP. No. 493 (1934).
13. Adverse Agency Publicity (Recommendation 73-1), 1 C.F.R. § 305.73-1 (1974).
14. Id.
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therein." 15 In a footnote, the ACUS distinguishes publicity from "the mere
decision to make records available to the public rather than preserve their
confidentiality[,]" as directed by criteria established in the Freedom of
Information Act.1 6 There is no further elaboration on the scope or format
of actions and policy that are used by an agency in this context. The
recommendation further emphasizes the potential for serious, and often
unfair, injury to the regulated party and rebukes such publicity when
"erroneous, misleading or excessive or it serves no authorized agency
purpose." 17
The ACUS recommendation also expressly notes that some agencies
utilize adverse publicity as their primary enforcement method and
recognizes that such publicity is not typically subject to judicial review. 18
The document also sets forth five standards for agency use of adverse
publicity: (1) that the publicity be factual and accurate, avoiding disparaging terms; (2) that publicity relating to regulatory investigations should
issue only in limited circumstances (and listing those circumstances);
(3) that the publicity should issue only after an agency has taken reasonable
precautions to assure the accuracy and verify an authorized purpose; (4)
that, where appropriate, the target of the adverse publicity be given advance
notice and reasonable opportunity to prepare a response; and (5) that, if the
publicity is shown to be erroneous or misleading, the agency issue a
retraction or correction.19
The Department of Health, Education, and Welfare-now the
Department of Health and Human Services ("DHHS")-also codified
regulations following the issuance of the ACUS recommendation. 20 These
regulations are directly binding on the FDA, as an agency within the DHHS.
In the DHHS codification, adverse information is defined as "any statement
or release by the Department or any principal operating component made to
the news media inviting public attention to an action or a finding by the
Department or principal operating component of the Department which may
adversely affect persons or organizations identified therein." 2 1 Although
parsed into subsections, the substance of the regulations is nearly identical
to that of the ACUS recommendation. 22 The legal impact of the DHHS
regulation binds the FDA to follow it as law applicable to the agency. In
15. 1 C.F.R. § 305.73-1.
16. § 305.73-1(a)n.1.
17. § 305.73-1.
18. § 305.73-1(b).
19. § 305.73-1.
20. See generally Release of Adverse Information to the News Media, 45 C.F.R.
(1976).
21. § 17.1.
22. §§ 17.1-.7.

§§

17.1-.7
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1977, the FDA published a notice of proposed rulemaking that described
intentions to issue a rule further directing the agency's use of adverse
publicity. 23 However, the proposed rule was never finalized.
B. Assessing Adverse Publicity in the Scholarly Literature
The administrative law literature is an extremely useful resource to
define the phrase "adverse publicity" as a foundational matter, as well as to
compare it with the FDA's practice of issuing warning letters for perceived
violations of the statute and regulations. The target audience of each
mechanism of communication has traditionally been viewed as distinct and
acutely relevant to the issue of whether one versus the other furthers the
protection of the public health. On the one hand, adverse publicity targets
a broad audience utilizing a range of outlets, including print, social media,
and internet. Adverse publicity is wide-ranging in the scope and focus of
the message. On the other hand, warning letters are drafted in a templated
fashion and targeted directly to an individual or company. Although
warning letters are publicly available on the FDA's website, a consumer,
medical specialist, or other interested party must actively search for such a
communication and be able to comprehend the complexities of the
regulations and laws as detailed in the letter. Part II attempts to disentangle
the purpose, audience, and intent of adverse publicity as compared to
enforcement through warning letters. However, as Part IV will emphasize,
the two communications are now typically cross-referenced through
electronic means and are no longer completely separate.
On the first page of his seminal article, Professor Ernest Gellhorn
defines adverse publicity as "affirmative measures taken by an agency
which, by calling public attention to agency action, may adversely affect
persons identified in the publicity." 24 He defines the roles of adverse
publicity to inform the public and regulated parties about the agency's
mission, policies, and performance; to warn the public of imminent harm;
and to punish or deter legal violations. 25 However, he does not deem these
26
categorizations mutually exclusive.
Gellhorn considers announcing administrative policy or action to be
the primary role of agency publicity. 27 Such publicity brings attention to
information that might otherwise be ignored, informs those regulated by the
23. Administrative Practices and Procedures: Publicity Policy, 42 Fed. Reg. 12,436-02 (Mar. 4,
1977).
24. Gellbom, supra note 1, at 1381.
25. Id. at 1382.
26. Id. at 1382 n.6.
27. Id. at 1382. Gellhom reminds readers that not all publicity is "adverse," especially the
informational variety. Id. at 1382 n.6.
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agency of new policies, aids in administrative efficiency by anticipating
questions, and promotes fairness by serving as notice. 28 He contrasts
agency announcements with another type of "informational" publicityagency warnings. 29 Agency warnings can be more controversial, because
within a certain context, warnings are desirable and necessary-for
example, the threat of serious and imminent physical or economic harm.
However, defining the scope of imminent physical or economic harm that
justifies the use of adverse publicity can be particularly difficult in
practice. 30
Finally, Gellhorn stipulates that, on occasion, publicity can be used to
punish, deter, or force transgressors to negotiate or settle, defining these
uses as "sanctions." 3 1 While Gellhorn notes that agency publicity has, at
times, been issued solely for the purpose of injuring or sanctioning the party,
more often, sanctions are issued along with information or a warning aimed
toward public consumption. 32 Individual types of publicity (e.g., warning
letters, press announcements, and talk papers) are not defined. Gellhorn
primarily uses "voluntary recalls" as examples of adverse publicity in his
FDA-specific analysis. 33
Professor Lars Noah sees agency "arm-twisting" in licensing,
government contracting, and enforcement proceedings. 34 In a 1997 article,
he discusses warning letters within his analysis of government contracting. 35 His analysis of adverse publicity, like that of Professor Gellhorn,
focuses more on the FDA's authority to compel a "voluntary recall." 36
More recently, Noah criticized 21 U.S.C. § 375(b) for being so ambiguous
in scope as to essentially empower the FDA to exercise extrajudicial
authority. 37 He cites Professor Gellhorn's strong statement: "Publicity is

28. Id. at 1383. Professor Nathan Cortez recognizes these uses in his note, as well. Cortez, supra
note 5, at 1379-80.
29. Gellhorn, supra note 1, at 1383.
30. Id. Gellhom notes that often the harm that results from informational publicity is because it
has a "gross" impact-the agency wields publicity like a machete where a scalpel would suffice. Id. at
1405.
31. Id. at 1382.
32. Id.
33. Id. at 1407-16.
34. Lars Noah, Administrative Arm-Twisting in the Shadow of Congressional Delegations of

Authority, 1997 wis. L. REV. 873, 876.
35. Id. at 886. warning letters traditionally advised the addressee that the government purchasing
entities had been advised to stop dealing with them until remedial action was taken. This no longer
happens.

36. Id. at 887; see also Lars Noah, The Little Agency That Could (Act with Indifference to
Constitutionaland Statutory Strictures), 93 CORNELL L. REV. 901 (2008) (also focusing on the FDA's

ability to use publicity to extra-statutorily "encourage" recalls, in addition to licensing contingent on
post-market surveillance).
37. Lars Noah, Governanceby the Backdoor: AdministrativeLaw(lessness?) at the FDA, 93 NEB.
L. REV. 89, 128-29 (2014).
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quicker and cheaper [than other enforcement measures]; it is not presently
subject to judicial review or other effective legal control; and it involves the
exercise of pure administrative discretion." 38
Within his article, Professor Noah also discusses Professor Tim Wu's
"Agency Threats." 39 Wu argues that
[t]hreat regimes . .. are important and are best justified when the industry
is undergoing rapid change-under conditions of "high uncertainty."
Highly informal regimes are most useful, that is, when the agency faces
a problem in an environment in which facts are highly unclear and
evolving. ... Conversely, in mature, settled industries, use of informal
40
procedures is much harder to justify.

He distinguishes public and private agency threats-explicitly categorizing
warning letters as a form of private threat. 4 1 He states "[t]he greatest
42
Professor Wu
advantage of a threat regime is its speed and flexibility."
refers to an inappropriate use of adverse publicity as a "conviction by press
release." 43 Wu writes,
Threats are not intended as a permanent solution, but rather as part of a
longer process. If successful and widely respected, it is possible that a
threat may create an industry norm, removing the need for rulemaking at
all. Alternatively, a threat regime may be a pilot, as it were, for eventual
lawmaking. The law created by rulemaking or adjudication will then
44
benefit from the facts developed under the threat regime.

Professor Nathan Cortez has explored the use of adverse publicity in
the internet era, connecting his research with that of Gellhorn. Cortez
comments on the sheer range of internet sources utilized by the FDA, stating
"[t]he FDA ... issues adverse or negative publicity in over two dozen
different formats, including press releases, warning letters, and a m6lange
of advisories, alerts, notifications, and updates-not to mention multiple
45
Twitter feeds and the voluminous information it releases on its website."
Cortez's research and analysis of internet sources primarily examines
46
In his
"Press Announcements" published on the FDA's website.
in
role
specific
its
on
focuses
Cortez
publicity,
of
adverse
introduction
47
underGellhorn's
on,
He recognizes, and elaborates
sanctioning firms.
standing of sanctions as a way for agencies to amplify statutory enforcement

38.
39.
40.
41.
42.
43.
44.
45.
46.
47.

Id. at 129 n.173 (quoting Gellhom, supra note 1, at 1424).
Id. at 124 n.155.
Tim Wu, Agency Threats, 60 DUKE L.J. 1841, 1842 (2011).
Id. at 1844.
Id. at 1851.
Id. at 1855-57.
Id. at 1851.
Cortez, supra note 5, at 1375.
Id.
Id. at 1378.
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powers. 4 8 He notes that adverse publicity often precedes or accompanies
more traditional or formal enforcement. 49 Cortez, like Gellhorn, defines
problematic agency publicity as publicity that is "erroneous, misleading or
excessive or it serves no authorized agency purpose." 50 He also characterizes adverse publicity as "a perfect example of what Professor Noah
calls extrastatutory 'arm-twisting."' 5
In the accompanying footnote,
Cortez further states, "Professor Noah defines 'arm-twisting' as 'a threat by
an agency to impose a sanction or withhold a benefit in hopes of
encouraging "voluntary" compliance with a request that the agency could
not impose directly on a regulated entity.' This definition encompasses, and
Professor Noah thus addresses, adverse publicity." 52
Later in his article, Cortez stipulates that while "the FDA does not
routinely publicize the enforcement actions it initiates-such as issuing a
Warning Letter or even signing a consent decree-it does announce a
significant number of these actions in press releases, and posts virtually all
of them on its website." 5 3 He further states that, while press releases sound
less threatening than warning letters, "both types of documents can
constitute a form of punishment against companies that the FDA suspects
are violating its regulations." 54 He lists warning letters as a specific form
of FDA news announcements (along with media transcripts, press
announcements, press releases, and talk papers). 55 However, Cortez later
characterizes FDA warning letters as a "passive" form of adverse publicity,
in the sense that the FDA posts the information publicly on its website, but
does not draw much attention to it. 56 He also states, "[l]ike Warning Letters,
which the FDA defines by regulation as informal enforcement actions, the
FDA considers adverse publicity to be a statutorily authorized form of
informal enforcement." 57 Although never explicitly stated, it seems as
though Cortez conceptualizes warning letters as distinct from "adverse
publicity."
Professor Cortez's report to the ACUS explicitly addresses the
definition of "agency publicity." 58
Cortez first quotes Gellhorn's

48.

Id. at 1379 ("Agencies also use adverse publicity as a more efficient pressure point to achieve

goals authorized by statute.").
49. Id.
50. Id. at 1382 (citing Adverse Agency Publicity (Recommendation No. 73-1), 1 C.F.R. § 305.73-1
(1974)).
51. Id. at 1392.
52. Id. at 1392 n.123 (citing Noah, supra note 34, at 874).
53. Id. at 1408.
54. Id. at 1409.
55. Id. at 1410.
56. Id. at 1411. However, he also notes that the FDA sometimes publicizes warning letters. Id.
57. Id. at 1414.
58. See CORTEZ, supra note 6, at 6.
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Recommendation 73-1, defining adverse agency publicity as "statements
made by an agency or its personnel which invite public attention to an
agency's action or policy and which may adversely affect persons identified
therein." 59 He notes that, traditionally, the ACUS distinguished adverse
publicity from the "mere decision" to make records public. 60 However, in
the internet era, the distinction between active and passive disclosure is
murky. 6 1 Cortez states that his previous research was focused on active
disclosure, but the ACUS report considers both active and passive
disclosures. 62 Furthermore, Cortez writes, "[i]n the past, FDA has used
publicity as a regulatory tool, treating both publicity and warning letters as
a form of informal enforcement." 63 He discusses warning letters in further
detail, clarifying that they are characterized as informal enforcement
because, typically, warning letters are used to notify individuals and firms
before formal enforcement measures are taken. 64 Cortez quotes the FDA's
Regulatory Procedures Manual, which states, "[a] Warning Letter is the
agency's principal means of achieving prompt voluntary compliance" with
the statute and regulations. 6 5 Cortez lists warning letters among other forms
of publicity, 66 but often refers to them as distinct from "publicity." 67
Cortez offers that the FDA no longer views publicity as an enforcement
tool. Rather, it views publicity as necessary for providing relevant health
information to the public, given the FDA's statutorily-mandated mission to
promote and protect the public health, and given the broad scope of
consumer products the FDA regulates (e.g., drugs, medical devices, foods,
and tobacco). 68 This passage recognizes a shift within the FDA toward
using publicity to inform and warn the public, rather than those it regulates.
Warning letters, themselves, are undoubtedly an enforcement tool. Press
announcements about warning letters or the publication of warning letters
on the FDA website could be viewed as informing or warning the public
and, therefore, as adverse publicity.

59. Id. (citing Adverse Agency Publicity (Recommendation No. 73-1), 1 C.F.R. § 305.73-1(a)
(1974)).
60. Id.
61. Id.
62. Id. at 7. Cortez specifically references the FDA's warning letter database. Id. at 20.
63. Id. at 31. This quote is pulled from the same paragraph as the statement "[c]urrent FDA
officials stress that the FDA no longer views publicity as an enforcement tool," perhaps suggesting that
the FDA now relies exclusively on warning letters to serve that purpose. Id.
64. Id. at 39.
65. Id. at 40; see also U.S. FOOD & DRUG ADMIN., REGULATORY PROCEDURES MANUAL § 4-1-1
(Mar. 2020), https://www.fda.gov/media/71878/download [https://perma.cc/V3NE-DPYP].
66. CORTEZ, supra note 6, at 39.

67. See, e.g., id. at 31, 104, 108 (writing consistently "publicity and Warning Letters" or "Warning
Letters and accompanying publicity").
68. Id. at 31-32.
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Cortez provides a comprehensive overview of 21 U.S.C. § 375(b) litigation (as well as actions against other agencies for use of publicity). 69
Only one case involved the use of warning letters. 70 Perhaps coincidently,
that same case is also the closest a court has ever come to doing more than
simply admonishing the FDA for reckless use of publicity. 7 1 A more recent
case worth highlighting is Dimare Fresh, Inc. v. United States, in which
tomato producers (whose crop was subject to an FDA warning for
salmonella contamination, later discovered to be unfounded) attempted a
"takings" argument. 72 However, the court did not adopt the producers'
argument, citing familiar counterarguments 73
In a subsequent 2018 article, Cortez writes that the goal of disclosure
of certain information may not always be to inform, but rather to persuade. 74
He continues, "[a]fter all, is the Surgeon General's Warning on tobacco
products meant to tell consumers something they do not already know?" 75
Cortez's work suggests that whether something is effective adverse
publicity may depend on the motivation behind the publication and on the
audience to whom it is directed. Other scholars have explored the aspect of
audience in the context of adverse publicity and tobacco, concluding that

69. Id. at app. C: Table of Fed. Cases (1974-2014).
70. See Den-Mat Corp. v. United States, No. MJG-92-444, 1992 U.S. Dist. LEXIS 9255 (D. Md.
Apr. 24, 1992). Notably, the letters were accompanied by a spokesperson's comments to the media. Id.
at *3-4.
71. See id. at *14 (observing that it would be "inherently unfair" to allow the FDA to use publicity
to enforce its determination "without allowing the affected party an opportunity to prove that the FDA's
position is wrong"). The court denied the FDA's motion to dismiss; however, there is no record of
subsequent case law. CORTEZ, supranote 6, at 9. For examples of courts' ratherempty condemnations,

see FisherBros. Sales, Inc. v. United States, 46 F.3d 279, 282 (3d Cir. 1995) (ruling in favor of the FDA
for fear that extensive tort liability would chill the agency from taking similar action to protect the
public's health in the future); Ajay Nutrition Foods, Inc. v. FDA, 378 F. Supp. 210, 212, 218 (D.N.J.
1974), aff'd mem., 513 F.2d 625 (3d Cir. 1975) (upholding the FDA's use of publicity, even when the
FDA allegedly called health food and dietary supplement manufacturers "quacks" and "faddists");
United States v. Abbott Lab'ys, 505 F.2d 565, 571 (4th Cir. 1974) ("[W]e join in the district court's
condemnation of this conduct and express our strongest disapproval that highly placed legal officers
would make a statement of this import with regard to a pending criminal prosecution, and even more so
that the FDA, which had referred the matter to the Department of Justice, would issue a press release
containing such prejudicial material."); and Wash. Legal Found. v. Kessler, 880 F. Supp. 26,34 (D.D.C.
1995) (noting that the FDA's publicity practices allow it to "effectively regulate industry without ever
exposing itself to judicial review").
72. Dimare Fresh, Inc. v. United States, 808 F.3d 1301 (Fed. Cir. 2015) (equating the public
warning with a quarantine), cert. denied, 136 S. Ct. 2461 (2016). In support of their argument in Court
of Federal Claims, Plaintiffs cited Yancey v. United States, 915 F.2d 1534 (Fed. Cir. 1991) (holding
quarantine of undiseased turkey flock was a taking). Dimare Fresh, Inc. v. United States, 118 Fed. Cl.
455, 461 (2014).
73. Dimare, 808 F.3d at 1311 (arguing that the warnings were not coercive or binding because
they did not prevent the producers from selling their crop-the unfortunate reality that the warnings left
the producers without any customers was unpersuasive to the court). The court also raised the familiar
counterargument that the FDA should be granted substantial deference in its work to protect the public
health. Id. at 1310-11.
74. Nathan Cortez, Regulation by Database, 89 U. COLO. L. REv. 1, 5 (2018).
75. Id.
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the FDA's publicity power is virtually ineffective against the Big Tobacco
advertising machine. 76
II. DISENTANGLING ADVERSE PUBLICITY AND ENFORCEMENT

Many theories exist that attempt to explain the FDA's shift away from
its view of adverse publicity as an enforcement tool to its utilization of more
formal mechanisms, such as warning letters, to urge compliance. For
example, one study of the FDA found that as media coverage of the FDA's
consumer protection responsibilities became more positive, the agency
issued enforcement decisions (warning letters) more slowly, whereas more
critical media coverage resulted in quicker action by the FDA. 77 The
researchers found that the effect was moderated by media salience-it was
only observed during "periods in which press coverage was relatively
intense," 78 such as in time of crisis or national emergency. 79 While an
assessment of these theories and relevant supporting evidence is outside the
scope of this Article, the discussion informs the quantitative assessments
provided in Part III regarding FDA activity in the time of COVID-19.
The FDA has numerous options to carry out the agency's functions
authorized by statute. The FDA's traditional command and control
regulatory approach to compliance is grounded in applying punitive and
deterrent regimes to achieve desired regulatory outcomes. There is rich
literature discussing approaches to regulation that supports industry
compliance. Ian Ayres and John Braithwaite, for example, have framed a
basic approach as "responsive regulation" depicted as an enforcement
pyramid with a "range of interventions of ever-increasing intrusiveness
(matched by ever-decreasing frequency of use)." 80 Some commentators
have characterized the FDA as specifically employing a "coercive
approach" to enforcement. 8 1 In order to achieve regulatory outcomes, the
FDA has a range of administrative and enforcement tools at its disposal to
monitor and respond to industry behaviors.

76. Patricia J. Zettler, The Indirect Consequences of Expanded Off-Label Promotion, 78 OHIO ST.
L.J. 1053, 1076 n.138 (2017).
77. Moshe Maor & Raanan Sulitzeanu-Kenan, The Effect of Salient ReputationalThreats on the
Pace of FDA Enforcement, 26 GOVERNANCE 31, 31 (2013).

78. Id.
79. See, e.g., Sarah Taylor Roller, Raqiyyah R. Pippins & Jennifer W. Ngai, FDA 's Expanding
Postmarket Authority to Monitor and Publicize Food and Consumer Health Product Risks: The Need
for Procedural Safeguards to Reduce "Transparency" Policy Harms in the Post-9/J

Regulatory

Environment, 64 FOOD & DRUG L.J. 577 (2009).
80. IAN AYRES & JOHN BRAITHWAITE, RESPONSIVE REGULATION: TRANSCENDING THE
DEREGULATION DEBATE 6 (1992).

81. See generally Robert L. Glicksman & Dietrich Earnhart, Coercive vs. Cooperative
&

Enforcement: Effect of Enforcement Approach on Environmental Management, 42 INT'L REV. L.
ECON. 135 (2015).
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The enabling statutes grant the FDA with a variety of mechanisms to
address and respond to industry activities. At a general administrative level,
the FDA can communicate with consumers, industry, and medical
professionals through publicity and outreach. The agency routinely utilizes
its website to issue public alerts and share information about products or
regulated entities. It also directs letters and electronic communications to
medical specialists and pharmacists. Within its broad powers, the FDA can
enable product recalls, withdraw a product from the market, remove an
approved product indication, and issue a hold on clinical trials. Once a
violation is detected, the agency may issue a warning letter or cyber letter,
triggering a specific follow-up and close-out process on the part of industry.
Inspections of facilities and products are also commonplace, coupled with
an official Form 483 identifying observations made by inspectors, and may
result in warning letters or legal action. Enforcement may then be
effectuated with the assistance of the courts through a seizure action or
injunction.
In his 2013 article, CredibleDeterrence: FDA and the ParkDoctrine
in the 21st Century, Patrick O'Leary stipulates
[w]hile warning letters are not technically enforcement actions, in that
they are not legally binding on recipients and carry no penalties, [they
can be treated] as a form of enforcement due to their frequent use by FDA
and the real punitive effect that they can have in terms of negative
publicity. 82

O'Leary also provides a short description of the use of warning letters:
FDA centers and districts issue warning letters for a wide variety of
alleged violations. While they do not constitute final agency action, and
do not themselves carry any penalty, they undoubtedly have a negative
publicity effect for regulated companies, and allow the agency to
communicate its displeasure with a regulated entity openly without
committing to a costly enforcement action. While it is unlikely that FDA
would consider a warning letter as a substitute for criminal prosecution
in a case where the latter could be seriously considered, the widespread
use of these letters and their general effectiveness are evidence that
FDA's deterrent approach is succeeding, and that the agency's
relationship with regulated parties (most of whom are repeat players with
no desire to antagonize their regulator unnecessarily) is distinctively
83
asymmetrical.

O'Leary also notes the practical significance of warning letters being
available to consumers: "[t]he simple fact of an investigation, warning
letter, or some other official suggestion of impropriety can have substantial
82. Patrick O'Leary, Credible Deterrence: FDA and the Park Doctrine in the 21st Century, 68
FOOD & DRUG L.J. 137, 155 n.129 (2013).
83. Id. at 156.
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negative impacts on consumer impressions and employee morale, and can
inhibit a company's ability to retain or recruit employees." 84 However, the
technical drafting, targeted to an individual or corporate entity, and the need
to affirmatively search for the warning letter on the FDA's website, create
a barrier to access that does not exist with generally targeted communications through various outlets to the general public. The media may
identify such a letter and bring it to the attention of the general public, but
for the most part, these letters are not regularly mainstreamed.
The FDA issues thousands of warning letters per year across the
spectrum of products that the agency regulates, which includes drugs,
biologics, medical devices, food, cosmetics, dietary supplements, tobacco
products, veterinary drugs, and radiation-emitting products. The FDA
reported that between the period of January 2009 through May 14, 2020,
the agency issued a total of 3,141 warning letters: 127 for biologic products;
1,475 for medical device products; and 1,478 for drug products. 85 Those
numbers average to approximately 273 warning letters per year: 12 per year
for biologics; 128 per year for medical devices; and 128 per year for drugs. 86
In comparison, between the period from March 6, 2020, to June 30, 2020,
(roughly four months), the FDA issued 88 warning letters specifically
relating to COVID products spanning drug, biologic, and medical device
categories. 87 Part III qualitatively and quantitatively assesses the scope and
content of those warning letters, which are publicly available on the FDA's
website. 88
The FDA accomplishes dissemination of information directly to the
public in various ways, often in tandem with the issuance of a warning letter.
These outlets to the public include press releases, either online or in print
media, broad-based safety announcements, or topical informational
webpages established to address a public health concern or set of products.
Over the same four-month period studied for issuance for warning letters,
the FDA published 152 press announcements in varying formats.
Increasingly, given online modalities and capabilities, the FDA cross-

84. Id. at 163.
85. FDA Dashboard: FDA Compliance Actions, U.S. FOOD & DRUG
datadashboard.fda.gov/ora/cd/complianceactions.htm

ADMIN.,

https://

(content current as of May 14, 2020).

86. These averages are based on approximately 11.5 years of data contained in the database
(January 2009-May 14, 2020).
87. Warning Letters, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/inspections-complian
ce-enforcement-and-criminal-investigations/compliance-actions-and-activities/waming-letters

(content

current as of June 22, 2020).
88. The FDA's publicity information regarding warning letters and adverse publicity, as
aggregated by the authors, is available in an Excel format through Google Documents. FDA Publicity
and Enforcement in the COVID Era - Raw Data, https://tinyurl.com/fda-publicity-covid

perma.cc/7H4K-T5V6].
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references and cross-links industry warning letters with information
targeted to the general public through these other online and print outlets.
IV. COVID-19 ENFORCEMENT AND ADVERSE PUBLICITY TRENDS

&

The current pandemic provides a substantial opportunity to study and
scrutinize the FDA's enforcement and publicity response to COVID-19. To
accomplish this, the authors of this Article proceeded along several routes
of agency communications both to industry and the general public. First,
the authors conducted a search of the FDA warning letter database to
identify COVID-related communications between January 1, 2020, and
June 30, 2020.89 The methodology was as follows: enter the search term
"COVID" in the search field; open and save each letter; and enter into an
Excel spreadsheet standardized information, including letter date, issuing
FDA Center, product type, legal authority cited, and entity type (e.g.,
company, individual). Second, the authors searched the FDA Press
Announcements webpage for any announcement specific to COVID
90
between January 1, 2020, and July 2, 2020, and similarly saved the results.
Upon substantive review of the announcements, the authors characterized
the focus of the COVID press announcements, including whether each
announcement reported on the issuance of a warning letter or a court
decision. Third, the authors searched the webpage entitled "Drug Safety
Availability" to determine whether there were any other COVID-related
communications. 9 1 Initially, the authors selected the link "Drug Safety
Communications" 92 and opened each communication listed under the
heading "2020" to establish whether any were relevant. After returning to
the Drug Safety & Availability page, the authors discovered a searchable
93
"Drug Safety Announcements" section. As with the warning letter methodology, the authors entered the search term "COVID," opened and saved
each result, and entered standardized information into a spreadsheet. Due
to similarity in function, the authors grouped together the documents
identified on the FDA Press Announcement webpage and the specific Drug
Safety & Availability webpage as "press announcements" in the description
of the findings.
89. Notably, the first warning letter related to COVID-19 was dated March 6, 2020. Warning
Letters, supra note 87.
90. Press Announcements, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/news-events/fda-

newsroom/press-announcements?page= (content current as of May 12, 2020). The first press announcement is dated January 27, 2020. Id.
91. Drug Safety & Availability, U.S. FooD & DRUG ADMIN., https://www.fda.gov/drugs/drugsafety-and-availability (content current as of July 13, 2020).
92. Drug Safety Communications, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/drugs/drugsafety-and-availability/drug-safety-communications (content current as of July 2, 2020).
93. Drug Safety & Availability, supranote 91.
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In total, the authors identified and assessed 88 warning letters with
dates spanning March 6, 2020, to June 30, 2020, and 152 press announcements with dates spanning January 27, 2020, to July 2, 2020. These findings
are described below.
A. Warning Letter Findings
The analysis of the warning letters revealed several aspects of
the FDA's activity in combating the promotion of unapproved and potentially dangerous products. The Center for Drug Evaluation and Research
("CDER") issued most of the warning letters, by far: 74 out of 88, or 84
percent. The warning letters issued by CDER have been consistent since
the declaration of the national emergency in the United States. While fewer
in number, the Center for Food Safety and Nutrition ("CFSAN") also issued
six letters spread out relatively evenly over the four-month span extending
from March through June. In comparison, the Center for Devices and
Radiological Health ("CDRH") issued all four of its letters within the same
week, close enough in time that the letters were described in a single press
announcement. 94 The Center for Biologic Evaluation and Research
("CBER") and the Center for Veterinary Medicine ("CVM") each issued
two warning letters. Table 1 depicts the warning letters by issuing Center

within the FDA.

94. Coronavirus (COVID-19) Update: FDA Issues Warning Letters to CompaniesInappropriately
MarketingAntibody Tests, PotentiallyPlacingPublic Healthat Risk, U.S. FOOD & DRUG ADMIN. (June
17, 2020), https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-

issues-warning-letters-companies-inappropriately-marketing-antibody [https://perma.cc/9KAG-6LRE].
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Table 1: Warning Letters by Issuing Center Within the FDA

Issuing Center

Total Letters

Percentage of
Total

Center for Drug Evaluation and
Research (CDER) 95
Center for Devices and
Radiological Health (CDRH) 96
Center for Food Safety and

74

84.09

4

4.54

6

6.82

2

2.27

2

2.27

88

100

Applied Nutrition CFSA
Center for Biologics Evaluation
and Research (CBER) 97
Center for Veterinary Medicine
98

(CVM)
TOTAL

95. One letter was listed as issued by the United States, rather than a particular issuing center;
however, it is signed by the director of CDER. U.S. Food & Drug Admin., Warning Letter to
Chloroquineonline.com (May 18, 2020) [hereinafter Warning Letter to Chloroquineonline.com],
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/
chloroquineonlinecom-607725-05182020 [https://perma.cc/AX2M-U7CD].
96. One CDRH letter was not listed on the warning letter database. U.S. Food & Drug Admin.,
Warning Letter to KBMO Diagnostics, LLC (June 17, 2020), https://www.fda.gov/inspections607822
-06
compliance-enforcement-and-criminal-investigations/warning-letters/kbmo-diagnostics-llc172020 [https://perma.cc/2XPW-JRV5]. This letter was only found on the "Fraudulent Coronavirus
Disease 2019 (COVID-19) Products" page. See Fraudulent Coronavirus Disease 2019 (COVID-19)
Products, U.S. FOOD & DRUG ADMIN., https://www.fda.gov/consumers/health-fraud-scams/fraudulent-

coronavirus-disease-2019-covid-19-products (content current as of July 21, 2020). Otherwise the
database results (search term: COVID) and the Fraudulent Products page match.
97. This count includes one letter issued by the Office of Biological Products Operations Division
II, within CBER. U.S. Food & Drug Admin., Warning Letter to EUCYT Laboratories LLC
(June 4, 2020), https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/
warning-letters/eucyt-laboratories-llc-607182-06042020 [https://perma.cc/5ZWK-9NHP].
98. The CVM letters were not technically listed under the search term "COVID" on the warning
letter database but were included in a COVID-focused press announcement as animal products that the
FDA was concerned humans would resort to consuming. Coronavirus (COVID-19) Update: Daily
Roundup April 16, 2020, U.S. FOOD & DRUG ADMIN. (Apr. 16, 2020), https://www.fda.gov/newsevents/press-announcements/coronavirus-covid-19-update-daily-roundup-april-16-2020 [https://perma.
cc/HG2B-P6GW]. After identifying these two letters in the press announcement, the authors accessed
them from the same warning letter database as the other letters.
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The FDA's online database of warning letters also designates a
classification for the product type at issue in each warning letter: drugs,
cosmetics, medical devices, biologics, food and beverages, dietary
supplements, and animal and veterinary products. 99 Each product category
is statutorily defined by Congress and supplemented by FDA policy, and
that categorization determines the route to market and applicable legal
provisions. Table 2 depicts the FDA's classification of the warning letters
by relevant product type, with CDER in bold to highlight the issuance of
letters with product categories spanning drugs, food and beverages, and
animal and veterinary products. A single warning letter can also contain
more than one product classification. The authors identified three examples
containing more than one product classification by the FDA, which had the
effect of skewing the numbers when compared to Table 1 totals. 100 Like
CDER, both CFSAN and CBER issued warning letters addressing multiple
product types. This reflects products that were deemed in violation of the
statute or regulations by means of their claims pushing the products into
another regulatory category. For example, food products that make claims
that the product in any way intends to treat, cure, mitigate, or diagnose a
disease or condition (i.e., COVID-19) would classify that product as a drug
product for legal requirements and enforcement purposes even if otherwise
labeled and advertised as food for human or animal consumption.

99.

FDA Publicityand Enforcement in the COVID Era - Raw Data, supra note 88.

100. See, e.g., U.S. Food & Drug Admin., Warning Letter to North Coast Biologics (May 21, 2020),
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/

north-coast-biologics-607532-05212020 [https://perma.cc/5S38-H4UJ] (including "Biologics" and
"Drugs" classifications); U.S. Food & Drug Admin., Warning Letter to Natural Solutions Foundation
(May 19, 2020), https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investiga
tions/waming-letters/natural-solutions-foundation-605748-05 192020 [https://perma.cc/YS39-V3XG]

(including "Dietary Supplements" and "Drugs" classifications); U.S. Food & Drug Admin., Warning
Letter to Savvy Holistic Health dba Holistic Healthy Pet (Apr. 7, 2020), https://www.fda.gov/
-dba-holistic-healthy-pet-605915-04072020
Veterinary" and "Drugs" classifications).

[https://perma.cc/J6B2-49Y9]

(including

"Animal

&

inspections-compliance-enforcement-and-criminal-investigations/warning-letters/savvy-holistic-health
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Table 2: Warning Letters by Product Type

Product Type

Total

Total per Issuing Center

Drugs 101

76

CDER
CFSAN
CBER

73
2
1

Dietary Supplements

3

CFSAN

3

Medical Devices10 2

4

CDRH

4

Biologics

2

CBER

2

Food & Beverages

3

CFSAN

2

CDER

1

CVM

2

CDER

1

Animal & Veterinary

3

101. Two warning letters were not classified at all but were added to this tally based on implicit
classification found in the content of each letter. See U.S. Food & Drug Admin., Warning Letter to
CBD Gaze (May 26, 2020), https://www.fda.gov/inspections-compliance-enforcement-and-criminal262
020 [https://perma.cc/7PVv-BXL5]; U.S. Food
investigations/warning-letters/cbd-gaze-607299-05
& Drug Admin., Warning Letter to Apollo Holding LLC (May 21, 2020), https://www.fda.gov/inspect
ions-compliance-enforcement-and-criminal-investigations/warning-letters/apollo-holding-llc-60780705212020 [https://perma.cc/P994-YHBH]. The other 74 warning letters included the explicit FDA
classification of "Drugs."
102. One warning letter was not classified at all but was added to this tally based on implicit
classification found in the content of the letter. See U.S. Food & Drug Admin., Warning Letter to
Sonrisa Family Dental dba www.mycovidtestl9.com (June 15, 2020), https://www.fda.gov/inspectionscompliance-enforcement-and-criminal-investigations/warning-letters/sonrisa-family-dental-dba-www
mycovidtestl9com-607748-06152020 [https://perma.cc/2J85-6GYM]. The other three warning letters
included the explicit classification of "medical devices."
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All but three of the 88 warning letters were addressed to a corporate
entity.1 03 Notably, nine of the warning letters expressly mentioned the use
of the Amazon Associates program, where an associate's website
advertises, but does not necessarily offer, items for sale. The associate's
website instead links to a product's Amazon page for fulfillment. Amazon
is copied on all nine warning letters. From a statutory perspective, this is
relevant, because prohibited actors under the law include manufacturers,
distributors, representatives, and others in the chain of supply of the
regulated product. 104 The utilization of the Amazon platform enables more
widespread access to the product or information about the product.
Within the warning letters, the FDA relied on a spectrum of legal
05
authorities for alleged violations. In the human drug realm,1 the most
commonly cited trio of legal authority, in 76 of the 88 total letters, included
07
and
sale of an unapproved drug,1 06 general misbranding of a drug,1
interstate
in
product
misbranded
or
adulterated
an
of
introduction
commerce. 108 Other legal authority, in addition to this basic trio, includes
the additional prohibited act of tampering with a product while held for
0
sale;1 09 prescription drug violations;" violations of public health emer1
and violations of various subsections of the new drug, misgency;"
branding, and adulteration provisions. There were three warning letters that
cited a proposed rule regarding an over-the-counter ("OTC") monograph
for topical antimicrobial drug products'1 2 and two proposed rules amending

103. The exceptions included U.S. Food & Drug Admin., Warning Letter to benjaminmcevoy.com
(May 14, 2020), https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investiga
6
tions/warning-letters/benjaminmcevoycom- 07 149-05142020 [https://perma.cc/8246-H37C] (regarding a personal blog monetized through the Amazon Associates program); U.S. Food & Drug Admin.,
Warning Letter to Center for New Medicine/Perfectly Healthy by Connealy MD (May 11, 2020),
https://www.fda.gov/inspections-compliance-enforcement-and-criminainvestigations/waming-letters/

center-new-medicineperfectly-healthy-connealy-md-605804-05112020 [https://perma.cc/JR6R -EZ9K]
(offering advice from Dr. Connealy herself); U.S. Food & Drug Admin., Warning Letter to North Coast
Biologics (May 21, 2020), https://www.fda.gov/inspections-compliance-enforcement-and-criminal6 7 5 32 5 2
-0 12020 [https://perma.cc/S9 R4-N94S]
investigations/warning-letters/north-coast-biologics- 0
(containing evidence of Facebook and LinkedIn posts and comments where individual Johnny T. Stine
offered to vaccinate people).
104. Food, Drug, and Cosmetic Act § 301, 21 U.S.C. § 321 (2018).
105. Including those products classified as "Dietary Supplements" in Table 2.
106. See 21 U.S.C. § 355(a).
107. See § 352.
108. See § 331(a), (d). This included introduction of a product in violation of the provisions
regarding emergency permits.
109. See § 331(k). Thirteen additional letters identified this legal authority.
110. See § 353(b)(1).
111. Public Health Service Act § 319, 42 U.S.C. § 247d (2018).
112. Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final
Monograph for Health-Care Antiseptic Drug Products, 59 Fed. Reg. 31,402 (proposed June 17, 1994)
(to be codified at 21 C.F.R. pts. 333, 369).
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the tentative final monograph," 3 as well as the Coronavirus Aid, Relief, and
Economic Security ("CARES") Act.' 1 4
Notably, the Federal Trade Commission ("FTC") co-signed 65 of these
88 warning letters, indicating a strong collaborative effort between the two
regulatory agencies to curb unfair and deceptive practices during the
pandemic. A total of 58 of the 65 co-signed letters were signed by the
director of CDER and the FTC; six of the 65 were signed by the director of
CFSAN and the FTC; one of the 65 was signed by the director of CBER
and the FTC. As co-signor, the role of the FTC was seemingly to confirm
the stance and legal authority of the FDA. Only one letter varied from the
others in that it contained additional examples of illegal behavior supplied
by the FTC." 5 Those not co-signed by the FTC were either for traditional
Chinese medicine or homeopathic remedies, or they were products
advertised online through a specific website.116
Warning letters for the sale of other types of non-drug products
included four letters from CDRH; two of them cite to the definition of
device,"'7 adulterated device provisions,"1 8 failure to obtain premarket
approval"1 9 or investigational device status, 120 misbranding provisions,121
lack of notice to the FDA,1 22 introduction of an adulterated or misbranded
product into interstate commerce, 12 3 and tampering with a product while
held for sale.1 24 Two letters contained additional legal authority regarding
misuse of the FDA logo as a specific misbranding violation.1 25 There were
also two letters relating to biologic products and three relating to a food
product, with limited utility to a study of trends.
113. Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for
Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of
Administrative Record, 81 Fed. Reg. 42,912 (proposed June 30, 2016) (to be codified at 21 C.F.R.
pt. 310); Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for
Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of
Administrative Record, 80 Fed. Reg. 25,166 (proposed May 1, 2015) (to be codified at 21 C.F.R.
pt. 310).
114. The Coronavirus Aid, Relief, and Economic Security ("CARES") Act, Pub. L. No. 116-136,
§§ 3851-56. The provisions relate to procedural aspects regarding tentative final monographs for overthe-counter drug products. Id.
115. warning Letter to Center for New Medicine/Perfectly Healthy by Connealy MD, supra note
103.
116. For example, violative products advertised for treatment of COVID-19 were linked to the
following websites: https://roidsmall.to/, https://emedkit.com/, Antroids.com, Foxroids.com, https://
www.unitedpharmacies.md/, http://chloroquineonline.com/, and http://4nrx.md/.
117. See Food, Drug, and Cosmetic Act § 301, 21 U.S.C. § 321(h) (2018).
118. See 21 U.S.C. § 351(f)(1)(B).
119. See § 360e(a).
120. See § 360j(g).
121. See § 352(o).
122. See § 360(k).
123. See § 331(a).
124. See § 331(k).
125. See § 352(a).
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Over half of the warning letters have been resolved in a timely fashion.
As of June 30, 2020, 52 addressees had taken corrective action (59 percent
of total); 4 additional addressees had taken corrective action prior to the
warning letter issuing (64 percent of total, if added to above). However, 32
addressees had not taken corrective action (36 percent of total), including
Xephyr, LLC dba N-Ergetics and Genesis II Church, which are now subject
to federal court orders, as announced via a press announcement, and
discussed below.
Upon closer examination of the letters addressing drug products, an
unsurprising trend emerged: more warning letters were issued for certain
product types with which the FDA has recently had compliance trouble. 126
For example, 15 warning letters were issued for homeopathic or herbal
remedies.1 27 Specific products included "Homeopathic Genus Epidemicus," 128 marketed as a homeopathic medicine for the prevention of
COVID-19 symptoms, and boneset tea, 129 marketed to relieve a present
infection. Additionally, 9 warning letters were issued for CBD products.1 30
More precisely, products like "Restorative Botanicals Ultra High Strength
Hemp Oil Supplement" 13 1 and "NoronaPak"1 32 were marketed as regimens
to fight off a COVID-19 infection-the latter was claimed to be "pharmacist
curated."
The FDA has previously cited its "risk-based approach" to monitoring
both of these types of products.1 33 Due to the growing popularity of
126. See, e.g., Statement on the Agency's Efforts to Protect Patients From Potentially Harmful

Drugs Sold as Homeopathic Products,U.S. FOOD & DRUG ADMIN. (Oct. 24, 2019) [hereinafter Efforts
to

Protect

Patients],

https://www.fda.gov/news-events/press-announcements/statement-agencys-

efforts-protect-patients-potentially-harmful-drugs-sold-homeopathic-products [https://perma.cc/WF8D
-WJDD]; FDA Regulation of Cannabisand Cannabis-DerivedProducts, IncludingCannabidiol(CBD),
U.S. FOOD & DRUG ADMIN., https://www.fda.gov/news-events/public-health-focus/fda-regulation-

[https://perma.cc/JAH3-9PXN]
cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
(content current as of Oct. 1, 2020).
127. See Warning Letters, supra note 87. Addressees included: Herbal Amy Inc.; Vivify Holistic
Clinic; Carahealth; Homeomart Indibuy; Cathay Natural, LLC; Alternative Health Experts LLC DBA
Immunization Alternatives; NRP Organics Ltd; Earthley Wellness dba Modern Alternative Mama LLC;
Herbs of Kedem; Gaia Arise Farms Apothecary; The Art Of Cure; Dr. Dhole's Sushanti Homeopathy
Clinic; Chronic Lyme Treatments; White Eagle Native Herbs; Altemavita. In addition, it may be of
note that 11 more letters were issued for essential oil products.
128. U.S. Food & Drug Admin., Warning Letter to Dr. Dhole's Sushanti Homeopathy Clinic
(May 4, 2020), https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/
[https://perma.cc/9TUJ-ZN
warning-letters/dr-dholes-sushanti-homeopathy-clinic-607348-05042020
JP].
129. U.S. Food & Drug Admin., Warning Letter to Herbal Amy Inc, (Mar. 6, 2020),
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
/herbal-amy-inc-604813-03062020 [https://perma.cc/Y75K-BA7C].
130. See Warning Letters, supra note 87. Addressees included: CBD Online Store, Indigo Naturals,
Native Roots Hemp, NeuroXPF, Project 1600 Inc., CBD Gaze, Apollo Holding LLC, Noetic
Nutraceuticals, Nova Botanix LTD d.b.a. CanaBD.
131. Warning Letter to CBD Gaze, supra note 101.
132. Warning Letter to Apollo Holding LLC, supra note 101.
133. See sources cited supra note 126.
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homeopathic remedies and CBD products in the marketplace, the FDA
simply cannot effectively monitor them all; however, the agency's top
priority remains protecting the health and safety of the public.1 34 At this
time, the FDA considers the marketing of these specific types of products
as "substitute treatments" for serious or life-threatening diseases to be a
significant enough risk to public health to warrant agency intervention. 135
Consequently, in light of the COVID-19 pandemic, the substantial number
of warning letters issued for these specific products is unsurprising.
Furthermore, specific product types may have influenced the FDA's
decision-making regarding the format, and therefore the audience, of a
given publicity statement. The issuance of two different types of publicity
for two different types of hand sanitizer provides a strong example. On

April 23, 2020, May 7, 2020, and May 28, 2020, respectively, the FDA
issued a warning letter for a non-alcohol-based hand sanitizer. 136 Each
letter took particular issue with claims of time-specific extended efficacy
(i.e., "up to 24 hours of protection!").1 37 The FDA stated its concern that
the trusting consumer would substitute these products for hand-washing or
practicing adequate social-distancing, therefore propagating the spread of
COVID-19 and prolonging the pandemic.1 38 Contrast these warning letters
with a drug safety and availability announcement issued on June 19, 2020,
for a methanol-based hand sanitizer.1 39 In sharing this communication, the
FDA's primary concern was preventing methanol poisoning, which has
symptoms including nausea, headache, permanent blindness, seizures,
coma, or even death.' 4 0 Ten days later, the FDA updated the announcement

134. See sources cited supra note 126.
135. See sources cited supra note 126.

&

&

136. U.S. Food & Drug Admin., Warning Letter to Quadrant Sales & Marketing, Inc. (May 28,
2020), https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning
-letters/quadrant-sales-marketing-inc-607625-05282020 [https://perma.cc/NDB5-M48Y]; U.S. Food
Drug Admin., Warning Letter to Sanit Technologies LLC dba Durisan (May 7, 2020), https://
www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sanittechnologies-llc-dba-durisan-606050-05072020 [https://perma.cc/7GRR-Z264]; see also; U.S. Food
Drug Admin., Warning Letter to Prefense LLC (Apr. 23, 2020), https://www.fda.gov/inspectionscompliance-enforcement-and-criminal-investigations/warning-letters/prefense-Ilc-605488-04232020
[https://perma.cc/39CW-86WK].
137. See sources cited supra note 136.
138. See sources cited supra note 136; see also Coronavirus(COVID-19) Update: FDA Continues
to Ensure Availability of Alcohol-Based Hand Sanitizer During the COVID-19 Pandemic, Addresses
Safety Concerns, U.S. FOOD & DRUG ADMIN. (Apr. 27, 2020), https://www.fda.gov/news-events/press-

announcements/coronavirus-covid-19-update-fda-continues-ensure-availability-alcohol-based-hand-sa
nitizer-during [https://perna.cc/7S8N-V4XH] (warning consumers about fraudulent and ineffective
sanitizer products and containing a hyperlink to the Prefense LLC warning letter).
139. FDA Advises Consumers Not to Use Hand SanitizerProducts Manufactured by Eskbiochem,

U.S. FOOD & DRUG ADMIN. (June 29, 2020), https://www.fda.gov/drugs/drug-safety-andavailability/fda-advises-consumers-not-use-hand-sanitizer-products-manufactured-eskbiochem [https://
perma.cc/3TM2-TADP].
140. Id.
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to inform the public that the company producing the hand sanitizer had
41
However, a few days later, the
agreed to voluntarily recall its product.1
agency issued a new generalized warning regarding methanol-based hand
sanitizers. 142 As of July 20, 2020, the FDA's website listed 75 hand
14 3
sanitizer products that had tested positive for methanol.
These two types of hand sanitizers were regulated in different ways:
non-alcohol-based sanitizer with a warning letter and methanol-based
sanitizer with a drug safety and availability announcement. Drug safety and
availability announcements tend to be reported much more widely than an
average warning letter. For example, the FDA's June 19, 2020, an144
whereas concerns
nouncement was reported by major media outlets,
regarding non-alcohol-based hand sanitizers have been primarily reported
by the FDA. Perhaps the seriousness of methanol poisoning influenced the
FDA to issue a different, more penetrative form of publicity.
Similarly, the warning letter for Miracle Mineral Solution ("MMS")comprising chlorine dioxide, which when mixed with citric acid (as
instructed) creates a toxic bleach-was the only letter to receive its own
press announcement. 145 The FDA had previously warned the public about
the dangers of MMS, citing side-effects such as "severe vomiting, severe
diarrhea, life-threatening low blood pressure caused by dehydration and
acute liver failure."14 6 However, starting in March, the addressee Genesis
II Church began advertising the COVID-19-fighting properties of MMS
across its website, adding to previous claims that the solution can treat
14 7
It is possible that the
"autism, cancer, HIV/AIDS, hepatitis and flu."
141. Id.
142. FDA Updates on Hand Sanitizers with Methanol, U.S. FOOD & DRUG ADMIN.,
[https://
https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-hand-sanitizers-methanol
perma.cc/K94A-BM79] (refer to July 2, 2020 update).
143. Id.
144. See, e.g., Christopher Mele, F.D.A. Warns of Potentially Toxic Hand Sanitizers, N.Y. TIMES
(Aug. 5, 2020), https://www.nytimes.com/2020/06/22/health/fda-Eskbiochem-toxic-hand-sanitizervims.html [https://perma.cc/3EHS-FHQT]; Allen Kim, These 9 Hand Sanitizers May Contain a
Potentially Fatal Ingredient, FDA Warns, CNN (June 22, 2020, 6:53 PM), https://www.cnn.
com/2020/06/22/us/hand-sanitizer-fda-trnd/index.html [https://perma.cc/6T33-JXVG].
145.

Coronavirus (COVID-19) Update: FDA Warns Seller Marketing Dangerous Chlorine Dioxide

Products That Claim to Treat or Prevent COVID-19, U.S. FOOD & DRUG ADMIN. (Apr. 8, 2020),
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-warns-seller

-marketing-dangerous-chlorine-dioxide-products-claim [https://perma.cc/W2M5-62DL]. As a separate
note, this warning letter is unrelated to President Trump's suggestion to kill COVID-19 infection by
ingesting bleach. See Coronavirus: Outcry After Trump Suggests Injecting Disinfectant as Treatment,

BBC (Apr. 24, 2020), https://www.bbc.com/news/world-us-canada-52407177
49CB].

[https://perma.cc/PQ6K-

146. FDA Warns Consumers About the Dangerous and Potentially Life-Threatening Side Effects of

Miracle Mineral Solution, U.S. FOOD & DRUG ADMIN. (Aug. 12, 2019), https://www.fda.gov/newsevents/press-announcements/fda-wams-consumers-about-dangerous-and-potentially-life-threatening-

side-effects-miracle-mineral [https://perma.cc/2DXG-98TS].

147. Coronavirus (COVID-19) Update: FDA Warns Seller Marketing Dangerous Chlorine Dioxide
Products that Claim to Treat or Prevent COVID-19, supra note 145.
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severe side effects of ingesting MMS, coupled with previous attempts to
warn the addressee, resulted in the FDA issuing a press announcement for
this warning letter and not for others.
Finally, in addition to four warning letters issued specifically for
unapproved "chloroquine" products, 14 8 the FDA issued several press
announcements that discussed the prescription drug hydroxychloroquine
("HCQ"). This comprehensive publicity strategy was reportedly, at least in
part, a response to contrary messaging propagated within the executive
branch. 149 President Trump repeatedly referred to HCQ as a promising cure
for COVID-19, but little to no scientific evidence supported his claim.1 50
The President's comments left the FDA in a tricky position-although the
agency is authorized to prohibit off-label promotion made by drug
manufacturers, it does not have the authority to directly address the
President's statements. 15 1 Ultimately, the FDA decided to release a general
press announcement, clarifying that HCQ is only FDA-approved for the
treatment of malaria and arthritis.1 52 When President Trump later stated
that HCQ was "not going to kill anybody" and a man subsequently died
from ingesting an aquarium-cleaning product containing "chloroquine," the
FDA issued another press announcement advising consumers that
chloroquine is not equivalent to HCQ and that any HCQ administration
should be under the supervision of a medical professional. 15 3 On June 15,
2020, the FDA announced that it had revoked HCQ's Emergency Use
Authorization for the treatment of COVID-19.154

148. See Warning Letter to Chloroquineonline.com, supra note 95; U.S. Food & Drug Admin.,
Warning Letter to 4nrx.md (May 13, 2020), available at https://www.fda.gov/inspections-compliance-

&

enforcement-and-criminal-investigations/warning-letters/4nrxmd-6061 15-05132020 [https://perma.cc/
9FJH-9VBF]; U.S. Food & Drug Admin., Warning Letter to Dr. G's Marine Aquaculture, Inc. (Apr. 15,
2020), https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/waming
-letters/dr-gs-marine-aquaculture-inc-606979-04152020 [https://perma.cc/4PER-XQ9L]; U.S. Food
Drug Admin., Warning Letter to Fishman Chemical of North Carolina, LLC (Apr. 15, 2020), https://
www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/waming-letters/fishma
n-chemical-north-carolina-llc-606978-04152020 [https://perma.cc/9F6A-KFLH].
149. See Elizabeth Y. McCuskey, FDA in the Time of COVID-19, 45 ABA ADMIN. & REG. L.
NEWS, no. 3, 2020, at 7-8.
150. See id.; see also Philip Bump, Trump and Fox Went All-in on a Coronavirus Silver Bullet. But
Maybe the Wrong One, WASH. POST (Apr. 19, 2020, 6:00 AM), https://www.washingtonpost.com/
politics/2020/04/19/trump-fox-went-all-in-coronavirus-cure-what-if-they-picked-wrong-one/
[https://
perma.cc/HJ2L-H4Z9].
151. McCuskey, supra note 149, at 8.
152. Id.
153. Id. at 8-9; see also Coronavirus (COVID-19) Update: Daily Roundup April 16, 2020, supra
note 98.
154. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for

Chloroquine and Hydroxychloroquine, U.S. FOOD & DRUG ADMIN. (June 15, 2020), https://
www.fda.gov/news-events/press-announcements/coronavirus-covid-1 9-update-fda-revokes-emergency
-use-authorization-chloroquine-and [https://perma.cc/F3UX-V5GE].
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B. Press Announcement Findings
An analysis of the press announcements identified several important
aspects of the FDA's activity in this realm. Of the 152 press announcements
reviewed, 96 did not contain any form of adverse publicity regarding an
identified company or individual. These published announcements contained information, in the form of hyperlinks, directing consumers to
guidance documents, updates on FDA procedures, and announcements of
awarded emergency use authorizations for a drug, biologic, or medical
device product.1 55
The press announcements that linked to publications on the Drug
Safety Communications webpage were the strongest form of adverse
publicity reviewed. 156 The "Drug Safety Communications" webpage is
housed under the "Drug Safety and Availability" section of the FDA's
website.1 5 7 The purpose of the "Drug Safety and Availability" section of
the website is to provide information for consumers and health professionals
on new drug warnings and other safety information, drug label changes, and
58
This section
shortages of medically-necessary drug products.1
predominantly features a link to the "Drug Safety Communications"
59
During
webpage, as well as its own searchable list of announcements.1
contained
announcements
list
of
searchable
the
the timeframe analyzed,
four COVID-19-related publications: two drug safety communications, an
advisement on the use of Non-Steroidal Anti-Inflammatory Drugs
("NSAIDs") to soothe COVID-19 symptoms,1 60 and a warning issued spe16
cifically for hand sanitizer manufactured by Eskbiochem. 1 Unlike the
drug safety communications, the other announcements did not have a
corresponding press announcement.

155. For a careful analysis of the scope and impact of the FDA's emergency use authorizations
during COVID-19, see Barbara J. Evans & Ellen Wright Clayton, Deadly Delay: The FDA's Role in
America's COVID-Testing Debacle, 130 YALE L.J.F. 78 (2020).
156. FDA Updates on Hand Sanitizers with Methanol, supra note 142; U.S. FOOD & DRUG ADMIN.,
DRUG SAFETY COMMUNICATION: FDA CAUTIONS AGAINST USE OF HYDROXYCHLOROQUINE OR
CHLOROQUINE FOR COVID-19 OUTSIDE OF THE HOSPITAL SETTING OR A CLINICAL TRIAL DUE TO RISK
OF HEART RHYTHM PROBLEMS (Apr. 24, 2020) [hereinafter FDA CAUTIONS AGAINST USE OF
[https://perma.cc/Q39X-SL
HYDROXYCHLOROQUINE], https://www.fda.gov/media/137250/download

WP].
157. See Drug Safety Communications, supra note 92; Drug Safety & Availability, supra note 91.
158. Drug Safety & Availability, supra note 91.
159. Id.
160. FDA Advises Patients on Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for
COVID-19, U.S. FOOD & DRUG ADMIN. (Mar. 19, 2020), https://www.fda.gov/drugs/drug-safety-and[https://
availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19
perma.cc/Q6CJ-QAEL].
161. FDA Advises Consumers Not to Use Hand Sanitizer Products Manufactured by Eskbiochem,
supra note 139.
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Specifically, the drug safety communications cautioned against the use
of HCQ outside the supervision of a medical professional1 62 and provided
a general warning about methanol-derived hand sanitizers. 163 The fact that
these detailed announcements are accessible several places across the
FDA's website via various hyperlinks (from a press announcement, from
the Drug Safety and Availability page, as well as from the Drug Safety
Communications page) suggests the FDA wanted to ensure the public was
aware of the adverse effects of using these specific products. However, it
is noteworthy that the methanol-derived hand sanitizer communication has
since been removed from the Drug Safety Communications webpage,
although it is still accessible via the Press Announcement and the Drug
Safety and Availability page.1 64
Three press announcements exhibited adverse publicity by discussing
warning letters specifically.1 65 Across these three publications, a total of 11
warning letters were discussed and hyperlinked. However, an additional 60
warning letters were hyperlinked, among other agency updates, in
COVID-19-specific "Daily Roundup" press announcements, which the
FDA began publishing each weekday starting on March 23, 2020.
Moreover, there were seven press announcements that neither mentioned a
drug safety communication nor a warning letter that might also be viewed
as the FDA exercising adverse publicity. Two of these publications
announced the revocation of an emergency use authorization: one for the
use of chloroquine and HCQ to treat COVID-191 66 and one for an inaccurate
antibody test.1 67 Two other announcements voiced "concerns" regarding
test kits-one announcement called out a specific test kit for inaccuracy, 68

162. FDA CAUTIONS AGAINST USE OF HYDROXYCHLOROQUINE, supranote 156.
163. FDA Updates on Hand Sanitizerswith Methanol, supra note 142.

164. See Drug Safety & Availability, supra note 91.
165. Coronavirus(COVID-19) Update: FDA Issues Warning Letters to Companies Inappropriately
Marketing Antibody Tests, Potentially PlacingPublic Health at Risk, supra note 94 (announcing the

first medical device warning letters for fraudulent tests); Coronavirus(COVID-19) Update:FDA Warns
Seller Marketing Dangerous Chlorine Dioxide Products that Claim to Treat or Prevent COVID-19,
supra note 145; Coronavirus Update: FDA and FTC Warn Seven Companies Selling Fraudulent
Products that Claim to Treat or Prevent COVID-19, U.S. FOOD & DRUG ADMIN. (Mar. 9, 2020),
https://www.fda.gov/news-events/press-announcements/coronavirus-update-fda-and-ft-wam-seven-

companies-selling-fraudulent-products-claim-treat-or [https://perma.cc/7VXK-35SZ] (announcing the
first warning letters issued for fraudulent COVID-19 products).
166. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for
Chloroquineand Hydroxychloroquine, supra note 154.

167. Coronavirus(COVID-19) Update: FDA Revokes Emergency Use Authorizationfor Chembio
Antibody Test, U.S. FOOD & DRUG ADMIN. (June 16, 2020), https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chembio-anti

body-test [https://perma.cc/HF9U-P38K].
168. Coronavirus (COVID-19) Update: FDA Informs Public About Possible Accuracy Concerns
with Abbott ID NOW Point-of-Care Test, U.S. FOOD & DRUG ADMIN. (May 14, 2020),
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-l 9-update-fda-informs-pub
lic-about-possible-accuracy-concems-abbott-id-now-point [https://perma.cc/7A94-5AKZ].
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while the other announcement warned more generally against fraudulent
test kits and linked to the FDA's warning letter page.1 69 Another announcement assured the public that effective hand sanitizer would be available
throughout the pandemic, but also warned that sanitizer can be sold with
fraudulent claims, linking to a warning letter issued for a particular nonalcohol-based sanitizer.' 7 0 The final two announcements addressed the
FDA's actions to combat fraudulent products in general,1 7 1 including one
where the FDA announced the issuance of a consumer update advising
consumers to be aware of fraudulent tests, vaccines, and treatments.1 72
Three press announcements mentioned the initiation of litigation
related to fraudulent COVID-19 products. These involved three separate
legal actions taken by the FDA against products. On April 17, 2020, the
FDA publicly announced that federal Judge Kathleen M. Williams for the
U.S. District Court for the Southern District of Florida entered a temporary
restraining order against Genesis II Church of Health and Healing and
individual defendants Mark Grenon, Joseph Grenon, Jordan Grenon, and
Jonathan Grenon, for the marketing and sale of MMS products.1 73
Ultimately, a permanent injunction was issued against Genesis II Church.1 74
Almost two weeks later, on April 29, 2020, the FDA issued a press
announcement stating that "[w]ith support from the FDA's Office of
Criminal Investigations and Office of the Chief Counsel, the U.S.
Department of Justice announced today that a federal court in Utah has
169. Coronavirus (COVID-19) Update: FDA Alerts Consumers About Unauthorized Fraudulent
COVID-19 Test Kits, U.S. FOOD & DRUG ADMIN. (Mar. 20, 2020), https://www.fda.gov/news-

events/press-announcements/coronavirus-covid-19-update-fda-alerts-consumers-about-unauthorizedfraudulent-covid-19-test-kits [https://perma.cc/SF6L-PQQY] (linking to the warning letter database
generally; note that no specific companies were named).

170. Coronavirus (COVID-19) Update: FDA Continues to Ensure Availability of Alcohol-Based
Hand Sanitizer Duringthe COVID-19 Pandemic, Addresses Safety Concerns, supra note 138.
171. Coronavirus(COVID-19) Update: FDA Continues to Combat FraudulentCOVID-19 Medical
Products, U.S. FOOD & DRUG ADMIN. (May 7, 2020), https://www.fda.gov/news-events/press-

announcements/coronavirus-covid- 1 9-update-fda-continues-combat-fraudulent-covid-1 9-medical-prod
ucts [https://perma.cc/F9TZ-G4K4]; Coronavirus (COVID-19) Update: Daily Roundup, March 24,
2020, U.S. FOOD & DRUG ADMIN.

(Mar. 24, 2020), https://www.fda.gov/news-events/press-an

nouncements/coronavims-covid-19-update-daily-roundup-march-24-2020 [https://perma.cc/9ASU-JQ
Yw].
172. Coronavirus (COVID-19) Update: Daily Roundup, March 24, 2020, supra note 171; see also
Consumer Updates, Beware of Fraudulent Coronavirus Tests, Vaccines and Treatments, U.S. FOOD
& DRUG ADMrN., https://www.fda.gov/consumers/consumer-updates/beware-fraudulent-coronavirus-

tests-vaccines-and-treatments [https://perma.cc/U5XH-BR6J] (content current as of Sept. 21, 2020).
173. Coronavirus (COVID-19) Update: Federal Judge Enters Temporary Injunction Against
Genesis II Church of Health andHealing, Preventing Sale of Chlorine Dioxide ProductsEquivalent to
Industrial Bleach to Treat COVID-19, U.S. FOOD & DRUG ADMIN. (Apr. 17, 2020), https://
www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-federal-judge-enters-te

mporary-injunction-against-genesis-ii-church [https://perma.cc/6RF5-SSD3];see also United States v.
Genesis II Church of Health & Healing, No. 1:20cv21601, 2020 U.S. Dist. LEXIS 70031 (S.D. Fla. Apr.
17, 2020); supra notes 146-48 and accompanying text.

174. Order of Permanent Injunction, United States v. Genesis II Church of Health & Healing, No.
(S.D. Fla. July 9, 2020).

1:20cv21601
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entered an injunction halting the sale of various silver products, promoted
as treatments for COVID-19."175 The publication contained a hyperlink to
a more detailed announcement originating from the Department of
Justice. 176 In this case, the court issued a temporary restraining order
against defendant Gordon Pedersen and his companies, My Doctor Suggests
LLC and GP Silver LLC. This order was closely followed by an order to
177
On June 26, 2020, the court entered
freeze all of the defendant's assets.
178
among other things, required
order,
consent
The
order.
a final consent
and to post explicit
customers
the defendant to issue refunds to eligible
disclaimers on his websites disavowing the ability of his products to treat
COVID-19.179
Finally, on May 14, 2020, the FDA announced that a federal judge
entered a temporary restraining order against Xephyr LLC, also blocking
the sale of silver products. 180 A preliminary injunction was entered by the
court on May 27, 2020.181 As of July 20, 2020, a final decision was still

pending.
IV. CONCLUDING REFLECTIONS ON FDA's COVID
ENFORCEMENT AND PUBLICITY

The global COVID-19 pandemic has forced the FDA to respond in
myriad ways to support innovation in product development as well as to
protect the public health, including the issuance of warning letters and the
use of adverse publicity. This moment in public health history has provided
a narrow and discernable timeframe to study the mechanisms by which the
175. Coronavirus(COVID-19) Update: Daily Roundup April 29, 2020, U.S. FOOD & DRUG ADMIN.
(Apr. 29, 2020), https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-

daily-roundup-april-29-2020 [https://perma.cc/8NPQ-76TM].
176. Court Orders Halt to Sale of Silver Product Fraudulently Touted as COVID-19 Cure, U.S.

FOOD & DRUG ADMIN. (Apr. 29, 2020), https://www.fda.gov/inspections-compliance-enforcement-and-

criminal-investigations/press-releases/court-orders-halt-sale-silver-product-fraudulently-touted-covid19-cure [https://perma.cc/BYV6-VD9D]. In the press release Assistant Attorney General Jody Hunt

is

quoted: "[w]e work closely with our partners at the Food and Drug Administration and will move

quickly to shut down schemes that promote and sell unlawful products during this pandemic." Id.
177. Temporary Restraining Order and Order to Show Cause Why a Preliminary Injunction Should
Not Issue, United States v. My Dr. Suggests, LLC, No. 2:20cv00279 (D. Utah Apr. 28, 2020); Order
Freezing Assets, United States v. My Dr. Suggests, LLC, No. 2:20cv00279 (D. Utah Apr. 28, 2020).
178. Consent Order and Final Judgment, United States v. My Dr. Suggests, LLC, No. 2:20cv00279
(D. Utah June 26, 2020).
179. Id. at 3-6.
180. Coronavirus (COVID-19) Update: Federal Judge Enters Temporary Injunction Against
Xephyr LLC Doing Business as N-Ergetics, PreventingSale of ColloidalSilver Productsfor COVID-19,
U.S. FOOD & DRUG ADMIN. (May 14, 2020), https://www.fda.gov/news-events/press-announcements/

coronavirus-covid-l9-update-federal judge-enters-temporary-injunction-against-xephyr-llc-doing
[https://perma.cc/U49Q-F86G]; see also Order Granting Temporary Restraining Order, United States v.
Xephyr LLC, No. 6:20-cv-00140 (E.D. Okla. May 14, 2020).
181. Order of Preliminary Injunction, United States v. Xephyr LLC, No. 6:20-cv-00140 (E.D. Okla.
May 27, 2020).
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agency monitors and reacts to industry behaviors as they relate to the
protection of consumers. This analysis also provides an opportunity to
engage with the existing scholarship on the agency's use of adverse
publicity as distinct (or not) from enforcement activity. Based on these
findings, the authors offer a few modest reflections connecting the literature
and current FDA practices.
First, as a foundational matter, the FDA promotes transparency
through the utilization of timely publication and updating of information on
its website, as well as providing the means for the public to search the
agency website and databases. Much has changed since Gellhorn's 1973
publication regarding how agencies communicate information and how the
general public is able to access that information.
The observations
presented by Cortez in his scholarship on adverse publicity-that the FDA
employs a vast array of communications to inform and warn the publicare supported by these findings, as well.
Second, the information the FDA provides on its website is
interconnected through electronic hyperlinks within the different resources.
For example, most warning letters (80 percent) were linked in a press
announcement, and many were among a miscellaneous Daily Roundup of
COVID-19 news. In addition, each warning letter contained a link to a page
on the FDA website specifically listing fraudulent COVID-19 products. 182
Once a company is listed as an entity with fraudulent products, its name is
not removed from the list (although an asterisk will be placed next to its
name if it has taken corrective steps). As noted in Part III, drug safety communications were linked both in press announcements and on the Drug
Safety and Availability landing page. Generally speaking, the more serious
the violation or safety risk to the public, the more often the messaging was
cross-referenced and hyperlinked. Presumably, overlapping publicity reinforced the FDA's messaging across its website, allowing the information
to reach wider and more diverse audiences.
Third, whether passive publicity or something more, the COVID-19
warning letters effectively employed Gellhorn's original five standards for
agency use of adverse publicity as codified in the ACUS Recommendation
73-1. The information in each warning letter was factual and accurate.
Also, the warning letters provided several specific examples of violative
behavior, often with quoted text or links to the webpage of the addressee,
and did not contain disparaging terms. 183 The warning letters were issued
182. FraudulentCoronavirus Disease 2019 (COVID-19) Products, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019-covid-19-pr
oducts (content current as of July 7, 2020).

183. See Ajay Nutrition Foods, Inc. v. FDA, 378 F. Supp. 210, 218 (D.N.J. 1974). For example, no
letter contained the terms "quack," "faddist," or any other term conveying a value judgment. See id.
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for a stated specific purpose: to prevent the spread of misinformation during
the COVID-19 pandemic. Each warning letter contained a paragraph explaining why it was sent. In addition, the warning letters contained several
statutes authorizing action by the FDA. Each warning letter notified the
addressee that it had 48 hours to either (a) provide a plan for corrective
action or (b) explain to the FDA, via a COVID-specific email address, why
its content did not violate the cited statutes. While this aspect of the letters
is largely reflective of general FDA protocol regarding warning letters, it
specifically addresses concerns about the lack of response mechanisms
available to targets of agency publicity. Finally, the FDA instituted means
to communicate the corrective action taken by and the compliance of
addressees. Although the FDA has not been publishing retractions, it has
been marking warning letters that resulted in corrective action on its website
with an asterisk.
Last, and relatedly, it is unclear how certain warning letters were
resolved when not resolved through official closeout procedure. During the
timeframe under study, 36 percent of addressees of warning letters did not
take timely corrective action in response to the letter according to the FDA's
website; yet, according to the FDA's press announcements, the FDA has
84
Perhaps the
only pursued legal action against two of the addressees.1
closeout
the
manner,
other
some
in
agency reached agreement with entities
information had not been timely updated on the website, or the FDA
contemplated or initiated legal action after our study. Arguably, an unresolved warning letter has served the purpose of informing or warning the
public, with or without official sanctions following the warning letter itself.

184. See Coronavirus (COVID-19) Update: FederalJudge Enters Temporary Injunction Against
Genesis II Church of Health and Healing, supra note 173; Coronavirus (COVID-19) Update: Federal
Judge Enters Temporary Injunction AgainstXephyr LLC Doing Businessas N-Ergetics, supra note 180.

The third press announcement with reference to a court decision regards a case with defendants not
subject to an FDA warning letter.

